S2 E2: A Between the Biotech Waves Conversation with Peter Barrett

Between the Biotech Waves

Player FM - Internet Radio Done Right

تمت الإضافة منذ قبل three أعوام

المحتوى المقدم من Nessan Bermingham PhD. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Nessan Bermingham PhD أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

This Is Woman's Work with Nicole Kalil

1
QUALIFIED: How Competency Checking and Race Collide at Work with Shari Dunn | 284 33:58

منذ 9 أيام33:58

التشغيل لاحقا

قوائم

إعجاب

احب

33:58

In this episode, we delve into the concept of being "qualified" in the workplace, examining who gets labeled as such, who doesn't, and the underlying reasons. We explore "competency checking"—the practice of scrutinizing individuals' abilities—and how it disproportionately affects underrepresented groups, often going unnoticed or unchallenged. Our discussion aims to redefine qualifications in a fair, equitable, and actionable manner. Our guest, Shari Dunn , is an accomplished journalist, former attorney, news anchor, CEO, university professor, and sought-after speaker. She has been recognized as Executive of the Year and a Woman of Influence, with her work appearing in Fortune Magazine, The Wall Street Journal, Ad Age, and more. Her new book, Qualified: How Competency Checking and Race Collide at Work , unpacks what it truly means to be deserving and capable—and why systemic barriers, not personal deficits, are often the real problem. Her insights challenge the narratives that hold so many of us back and offer practical solutions for building a more equitable future. Together, we can build workplaces and communities that don’t just reflect the world we live in, but the one we want to create. A world where being qualified is about recognizing the talent and potential that’s been overlooked for far too long. It’s not just about getting a seat at the table—it’s about building an entirely new table, one designed with space for all of us. Connect with Our Guest Shari Dunn Website& Book - Qualified: https://thesharidunn.com LI: https://www.linkedin.com/today/author/sharidunn TikTok: https://www.tiktok.com/@thesharidunn Related Podcast Episodes: How To Build Emotionally Mature Leaders with Dr. Christie Smith | 272 Holding It Together: Women As America's Safety Net with Jessica Calarco | 215 How To Defy Expectations with Dr. Sunita Sah | 271 Share the Love: If you found this episode insightful, please share it with a friend, tag us on social media, and leave a review on your favorite podcast platform! 🔗 Subscribe & Review: Apple Podcasts | Spotify | Amazon Music…

منذ عام واحد 53:51

MP3•منزل الحلقة

Welcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary in the field, Peter Barrett.
Peter is a partner at Atlas Venture, where he has been a key player in the creation of numerous novel therapeutic and drug discovery platform companies. With an unyielding passion for advancing healthcare, Peter has been directly involved in co-founding, building, investing and supporting numerous companies including Celera Genomics, Alynlam Therapeutics and Momenta, to name just a few.
Known for his entrepreneurial spirit, Peter co-founded Celera Genomics, where he led groundbreaking work that culminated in the first successful sequencing of the human genome in 2001. His strategic insights propelled Celera into the public arena, and his leadership has shaped the trajectory of many biotech companies over the years.
In addition to his roles in the biotech sector, Peter is an Executive Fellow at Harvard Business School and serves as the faculty chair of the advisory board for the prestigious Blavatnik Fellowship Program, helping to cultivate the next generation of leaders in science and business.
Join me as we engage in a fascinating conversation with Peter Barrett, delving into his remarkable journey, the evolution of biotechnology, and the innovative spirit that drives his work.

38 حلقات

#Science #Trading #Biology #Business #Nessan Bermingham PhD

S2 E2: A Between the Biotech Waves Conversation with Peter Barrett

Between the Biotech Waves

published منذ عام واحد

MP3•منزل الحلقة

38 حلقات

#Science #Trading #Biology #Business #Nessan Bermingham PhD

كل الحلقات

1
S2 E4: A Between the Biotech Waves Conversation with Dan Lynch 1:01:00

منذ 7 أيام1:01:00

1:01:00

In this episode, I am thrilled to welcome Dan Lynch, an Executive Venture Partner at Google Ventures and a seasoned leader in the biotechnology sector. Since joining GV in 2021, Dan has partnered with life sciences CEOs and executives, providing invaluable guidance as a trusted advisor and coach. His commitment to fostering long-term relationships underscores his belief that collaboration is essential in an industry filled with talented people. Dan brings a wealth of experience, having worked with numerous biopharmaceutical companies, including notable names like ImClone, where he served as CEO and CFO. Under his leadership, ImClone achieved a remarkable turnaround and secured FDA approval for the groundbreaking cancer treatment ERBITUX®. With a focus on placing patients at the center of every initiative, Dan emphasizes the importance of impact and community in the biotech landscape. He currently serves on the boards of several innovative companies and has a rich history of successful investments and partnerships. Join us as we dive into Dan’s insights into the world of biotechnology, the importance of collaboration, his experience turning around ImClone and what it truly means to prioritize patient impact in this ever-evolving field.…

1
S2 E3: A Between The Biotech Waves Conversation with Stan Crooke, Ionis & N-Lorem Founder 1:04:50

منذ 14 يومًا1:04:50

1:04:50

In today's episode, I am honored to welcome Stanley Crooke, the founder and CEO of Ionis Pharmaceuticals the first and leading antisense oligonucleotide biotech and founder, CEO and Chair of N-Lorem, a not for profit entity developing ASOs for ultra rare diseases. Stan is THE pioneer in the field of antisense oligonucleotide based RNA-targeted therapies. With a deep passion for science and innovation, Stan has dedicated his career to transforming the landscape of drug discovery and development, resulting in groundbreaking therapies that address some of the most challenging diseases. Stan's journey in biotechnology is truly inspiring, he comes from a humble beginning in Indianapolis, he was the first in his family to graduate high school, following which he studied pharmacy and ultimately went on to obtain an MD and PhD, following which he embarked on a path that united his clinical expertise with cutting-edge research. Under his leadership, Ionis has become a leader in the development of antisense oligonucleotide technology, paving the way for new treatments for genetic disorders, neurodegenerative diseases, and many others. Throughout his career, Stan has emphasized the importance of collaboration and scientific rigor, and he has been instrumental in fostering partnerships that drive innovation in the industry. Join us as we explore Stan Crooke’s remarkable journey, his vision for the future of biotechnology, and the impact of Ionis Pharmaceuticals on patients worldwide.…

1
S2 E2: A Between the Biotech Waves Conversation with Peter Barrett 53:51

منذ 5 weeks53:51

53:51

Welcome to ‘Between the Biotech Waves,’ the podcast where we navigate the dynamic world of biotechnology and explore the minds driving its innovation. I’m your host, Nessan Bermingham, and today, we have a true visionary in the field, Peter Barrett. Peter is a partner at Atlas Venture, where he has been a key player in the creation of numerous novel therapeutic and drug discovery platform companies. With an unyielding passion for advancing healthcare, Peter has been directly involved in co-founding, building, investing and supporting numerous companies including Celera Genomics, Alynlam Therapeutics and Momenta, to name just a few. Known for his entrepreneurial spirit, Peter co-founded Celera Genomics, where he led groundbreaking work that culminated in the first successful sequencing of the human genome in 2001. His strategic insights propelled Celera into the public arena, and his leadership has shaped the trajectory of many biotech companies over the years. In addition to his roles in the biotech sector, Peter is an Executive Fellow at Harvard Business School and serves as the faculty chair of the advisory board for the prestigious Blavatnik Fellowship Program, helping to cultivate the next generation of leaders in science and business. Join me as we engage in a fascinating conversation with Peter Barrett, delving into his remarkable journey, the evolution of biotechnology, and the innovative spirit that drives his work.…

1
S2 Episode 1: A conversation with Matt Porteus 54:32

منذ 6 weeks54:32

54:32

Now that JPM '25 is behind us, where the weather was great but the mood was somber, back to podcasting! Welcome back to 'Between the Biotech Waves,' the podcast where we explore the frontiers of biotechnology and the remarkable individuals driving innovation. I’m your host, Nessan Bermingham, and today, we are honored to have Dr. Matt Porteus with us, a true pioneer in the field of genome editing. Dr. Porteus is making headlines for his role in the development of Lyfgenia, the groundbreaking CRISPR-Cas9 gene editing drug from Vertex Pharmaceuticals and CRISPR Therapeutics, designed to treat sickle cell disease. He recently founded Kamau Therapeutics, a company I am involved with, to develop a next gen curative therapy for sickle cell disease. Raised in California, Matt's academic journey began at Harvard University, where he graduated Magna Cum Laude with a focus on the ethics of recombinant DNA technology—a testament to his deep understanding of the intersection between science and society. He later completed his combined MD and PhD at Stanford Medical School, focusing on mammalian fore brain development. His postdoctoral research under Dr. David Baltimore at MIT and CalTech solidified his path toward developing innovative therapies using homologous recombination for genetic disorders, particularly in children. Returning to Stanford in 2010 as an Associate Professor, Dr. Porteus has led the way in demonstrating efficient gene correction in human cells, paving a path for curative treatments in pediatrics. His expertise extends beyond genetic diseases to include the dynamics of various pediatric conditions, with a hands-on role at the Lucille Packard Children’s Hospital, where he cares for young patients undergoing hematopoietic stem cell transplantation. Currently Matt is Sutardja Chuk professor of definitive and curative medicine. In today's episode, we’ll dive into Dr. Porteus's inspiring journey, the significance of Lyfgenia, and his vision for the future of gene editing in transforming the treatment of sickle cell disease and beyond.…

1
Episode 35: A Between the Biotech Waves Conversation with Mike Curtis, President & CEO of eGenesis 1:05:29

منذ 35 weeks1:05:29

1:05:29

Welcome back to Between the Biotech Waves. I am sorry for the lack of episodes over the past few months, unfortunately life threw me a curve ball that I have been taking care of but now back and ready to go! Today it gives me great pleasure to introduce Mike Curtis, President and CEO of eGenesis. You may recall seeing eGenesis on the front cover of the New York Times recently following the first successful xenotransplantation of a genetically modified porcine kidney. This followed years of work within eGenesis to develop porcine donors for human tissue transplant. Mike has a 25 year plus history in biotech from Infinity to Cadent where he played a critical role in the merger of Ataxion Therapeutics with Luc to Catabasis where he led product development and regulatory affairs to his current role as CEO and President at eGenesis. Mike earned his Ph.D. in Cell and Molecular Biology from the State University of New York Upstate Medical University. His story is fascinating. Please join me in welcoming Mike Curtis.…

1
Episode 33: A Between the Biotech Waves conversation with Eliot Forster, xCEO of F-star Therapeutics 1:04:37

منذ 2 years1:04:37

1:04:37

Today I am talking to Eliot Forster xCEO of F-star Therapeutics. Eliot was at helm of the company as they reversed merged into Springbank Pharmaceuticals & through the recently announced acquisition by Sino Biopharma, a transaction that generated a lot of interest given the very public interactions with CFIUS. Prior to F-star, Eliot was CEO of Immunocore, Creabilis and Solace Pharmaceuticals following his multiple roles at Pfizer which included head of development and operations, European Union. He was the founding chair of Medcity and is an honorary visiting professor of molecular and clinical cancer medicine at the University of Liverpool, to name just a few roles he has had. Eliot is a member of the board of directors of Immatics and is chair of the boards of Ochre Biosciences and Avacta.…

1
Episode 32: The Triplet Therapeutics story, from concept to birth, life & death. 1:45:49

منذ 2 years1:45:49

1:45:49

Today we have an unusual (& long) podcast where we talk to key members of the Triplet Therapeutics management team. Triplet was founded to develop antisense oligonucleotides targeting the DNA damage response pathway that has been implicated in driving repeat disorders including Huntington's disease - the lead indication for Triplet. The team discusses the challenges in building the company and what ultimately led to it's demise.…

1
Episode 31: A Between the Biotech Waves Conversation with Tim Yu 55:34

منذ 2 years55:34

55:34

Today we are talking to Tim Yu. Tim is attending physician at the division of genetics and genomics at Boston Children’s Hospital and assoc prof of Pediatrics at Harvard Medical School. The scope of work that Tim does is well beyond what can be covered in this intro however I have gotten to know Tim through his leading the emerging filed of N of 1 plus drugs. Tim worked with Julia Vitarello to develop Milasen leading the way in truly personalized therapeutics. Please join me in welcoming Tim to the podcast.…

1
Episode 30: A Between the Biotech Waves conversation with Barry Greene, CEO of Sage Therapeutics 45:57

منذ 2 years45:57

45:57

Today we are talking to Barry Greene, CEO of Sage Therapeutics. Barry has had an amazing career spanning over 30 years in the biotech industry. Prior to Sage Barry was President of Alnylam shepherding it with John through its evolution from basic science through commercial product launch. Prior to ALNY Barry was general manager of Oncology at Millennium where he was directly involved in the approval and launch of Velcade. He is currently a member of the board of the Pharmaceutical Research and Manufacturers of America.…

1
Episode 29: A Between the Biotech Waves conversation with Joel Marcus, Founder & Exec Chair of Alexandria Real Estate 53:19

منذ 2 years53:19

53:19

Today we are talking to Joel Marcus. He has shaped the life sciences industry through ARE from the buildings we use to venture and fund investing. His impact can be directly seen in major cities across the US from Boston to NY to San Francisco with over 22million sq ft of space. Beyond Alexandria he is a philanthropist who supports veterans and their families, and through his initiatives people suffering from the opioid crisis, homelessness and mental illness. Please join me in welcoming Joel.…

1
Episode 28 A Between the Biotech Waves Conversation with Rachel Meyers 57:39

منذ 2 years57:39

57:39

Today we are talking to Rachel Meyers. Rachel was most recently the CSO of Faze Medicines a company she launched with TRV to focus on the regulation of biomolecular condensates to treat disease. Prior to Faze she was an EIR at TRV prior to which she spent nearly 2 decades at Alnylam. I have had the pleasure of working with Rachel getting an appreciation not only of her as a scientist, entrepreneur and operator but also her pure love of science, focus on company culture and her passion for diversity, equity and inclusion.…

1
Episode 27 A Between the Biotech Waves Conversation with Aoife Brennan, CEO of Synlogic 1:06:59

منذ 2 years1:06:59

1:06:59

Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen ultimately becoming head of Rare Disease Innovation, she was involved in the development of Spinraza, Alprolix and Eloctate. Aoife moved from Biogen to Synlogic where she initially took the CMO role ultimately being elected as CEO and President of the company. She has led Synlogic since 2018. Beyond Synlogic Aoife is on the BoD of Cerevance and Fibrogen having also served on the board of RA Pharma through its acquisition by UCB. We discuss Aoife’s career trajectory, her experiences at Biogen and decision to join Synlogic. Navigating the failure of their lead program in 2020 as a public company and building a deep pipeline today. In addition we discuss diversity and inclusion in our biotech industry today and ways this could be more impactful. Please join me in welcoming Aoife.…

1
Episode 26: A Between the Biotech Waves conversation with Drew Weissman 57:08

منذ 2 years57:08

57:08

Today we are talking to Drew Weissman. Drew is the Roberts Family Professor in Vaccine Research at Perelman School of Medicine and Director of the Penn Institute for RNA Innovation at the University of Pennsylvania. Drew has spent his career working on RNA biology and vaccine development. He, along with his colleague Katalin Kariko, have been pivotal in the development of mRNA vaccines most notably the COVID-19 vaccines developed by BioNTech/Pfizer and Moderna. Drew received his MD/PhD from Boston University in 1987, following which he did a residency at Beth Israel and followship at the NIH under Anthony Fauci. He has received numerous awards including the Lasker-DeBakey Clinical Medical Research Award and Rosenstiel Award. Today we discuss Drew’s career trajectory, mRNA biology and vaccine development.…

1
Episode 25: A Between the Biotech Waves conversation with Rodolphe Barrangou, the Todd R Klaenhammer Distinguished Professor at NC State University. 1:00:19

منذ 2 years1:00:19

1:00:19

Today we are talking to Rodolphe Barrangou. Rodolphe is the Todd R Klaenhammer Distinguished Professor at NC State University. He is a scientist entrepreneur who has co-founded a multitude of biotech companies around CRISPR based approaches including CRISPR Biotechnologies, Ancilia Biosciences, TreeCo and Intellia Therapeutics. He is one of the pioneers in CRISPR-Cas9 dating back to his time as R&D director of genomics at DuPont. In 2007 Rodolphe was the lead author on a Science paper demonstrating proof of the immune function of CRISPR in bacteria.…

1
Episode 23: A Between the Biotech Waves conversation with Jim Birchenough, Vice Chair of Wells Fargo Biopharmaceutical Inv Banking 56:51

منذ 2 years56:51

56:51

I am delighted to welcome back Jim Birchenough to Between the Biotech Waves. Jim is Vice Chair Wells Fargo Biopharmaceutical Investment Banking. In 2022 Jim joined the podcast to discuss the market dynamics and learnings from prior market corrections. I am welcoming him back to take stock of where we are, what the bright spots in 2022 were and crystal ball gaze into ’23. What should be watching for as the start of the year unfolds.…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

الاستماع إلى +500 موضوع

Marvel Legends Series Daredevil: Born Again Daredevil Collectible 6-Inch Action Figure

TERRO T300B Liquid Ant Killer, 12 Bait Stations

everydrop by Whirlpool Ice and Water Refrigerator Filter 1, EDR1RXD1, Single-Pack , Purple

المدونة الصوتية تستحق الاستماع

Between the Biotech Waves « » S2 E2: A Between the Biotech Waves Conversation with Peter Barrett

S2 E2: A Between the Biotech Waves Conversation with Peter Barrett

المدونة الصوتية تستحق الاستماع

مرحبًا بك في مشغل أف ام!

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

The Let Them Theory: A Life-Changing Tool That Millions of People Can't Stop Talking About

Ailun 3 Pack Screen Protector for iPhone 16 Pro Max [6.9 inch] + 3 Pack Camera Lens Protector with Installation Frame,Sensor Protection,Dynamic Island Compatible,Case Friendly Tempered Glass Film

دليل مرجعي سريع

Between the Biotech Waves « »
S2 E2: A Between the Biotech Waves Conversation with Peter Barrett